GO
Loading...

Gilead Sciences Inc

More

  • As S&P nears 2,000, traders keep eye on earnings Tuesday, 22 Jul 2014 | 6:51 PM ET
    Traders work the floor of the New York Stock Exchange.

    Shaking off geopolitical flare-ups for now, analysts say the S&P 500 is taking aim at the 2000 level, and the next round of earnings news could help.

  • Final Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 6:02 PM ET

    Amgen Inc. rose $2.08 or 1.7 percent, to $121.11. Biogen Idec rose $1.17 or. 4 percent, to $303.67. Celgene Corp. rose $1.35 or 1.6 percent, to $86.66.

  • Midday Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Amgen Inc. rose $1.68 or 1.4 percent, to $120.71. Biogen Idec rose $2.64 or. 9 percent, to $305.14. Celgene Corp. rose $1.30 or 1.5 percent, to $86.61.

  • Early Glance: Biotechnology companies Tuesday, 22 Jul 2014 | 11:16 AM ET

    Amgen Inc. rose $1.30 or 1.1 percent, to $120.33. Biogen Idec rose $5.25 or 1.7 percent, to $307.75. Celgene Corp. rose $1.69 or 2.0 percent, to $87.00.

  • HIV pills show more promise to prevent infection Tuesday, 22 Jul 2014 | 2:31 AM ET

    There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.

  • US stocks mount strong rebound on company earnings Friday, 18 Jul 2014 | 8:53 AM ET

    The gains wiped out much of the market's losses from the day before, when the downing of a Malaysian Airlines passenger jet in eastern Ukraine stirred concerns that tensions between Russia and the West could escalate. Israel's launch of a ground offensive into Gaza also stoked geopolitical uncertainty.

  • July 17- UnitedHealth Group Inc, after wading cautiously into Obamacare insurance exchanges this year, on Thursday vowed to become a major player, participating in as many as two dozen state exchanges in 2015 and growing from there.

  • Midday Glance: Biotechnology companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Amgen Inc. rose$. 05 or percent, to $116.91. Biogen Idec fell $6.64 or 2.1 percent, to $305.36. Celgene Corp. fell$. 70 or. 8 percent, to $86.08.

  • Early Glance: Biotechnology companies Wednesday, 16 Jul 2014 | 11:11 AM ET

    Amgen Inc. rose$. 29 or. 3 percent, to $117.16. Biogen Idec fell $4.28 or 1.4 percent, to $307.72. Celgene Corp. rose$. 21 or. 2 percent, to $86.99.

  • July 15- Johnson& Johnson reported higher-than-expected quarterly revenue and earnings, benefiting from strong sales of its Olysio treatment for hepatitis C. Sales jumped 9.1 percent to $19.5 billion, beating Wall Street expectations of $18.99 billion.

  • Midday Glance: Biotechnology companies Monday, 14 Jul 2014 | 1:29 PM ET

    Amgen Inc. fell$. 54 or. 5 percent, to $119.23. Biogen Idec fell $2.91 or. 9 percent, to $319.31. Celgene Corp. fell $1.01 or 1.1 percent, to $88.18.

  • Early Glance: Biotechnology companies Monday, 14 Jul 2014 | 10:47 AM ET

    Amgen Inc. fell$. 27 or. 2 percent, to $119.50. Biogen Idec fell$. 76 or. 2 percent, to $321.46. Celgene Corp. fell$. 93 or 1.0 percent, to $88.26.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Midday movers: Amazon.com, Ford Motor, URS & More Friday, 11 Jul 2014 | 1:04 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Friday's midday movers:

  • July 11- Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.

  • Early Glance: Biotechnology companies Friday, 11 Jul 2014 | 10:30 AM ET

    Amgen Inc. rose$. 37 or. 3 percent, to $119.32. Biogen Idec fell $1.42 or. 4 percent, to $317.70. Celgene Corp. fell$. 05 or. 1 percent, to $87.78.

  • July 11- Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C, citing the expense to federal healthcare programs.

  • Midday Glance: Biotechnology companies Thursday, 10 Jul 2014 | 1:44 PM ET

    Amgen Inc. fell$. 81 or. 7 percent, to $118.76. Biogen Idec fell$. 39 or. 1 percent, to $319.75. Celgene Corp. rose$. 72 or. 8 percent, to $88.24.

  • Early Glance: Biotechnology companies Thursday, 10 Jul 2014 | 11:01 AM ET

    Amgen Inc. fell$. 89 or. 7 percent, to $118.68. Biogen Idec fell $3.10 or 1.0 percent, to $317.04. Celgene Corp. fell$. 60 or. 7 percent, to $86.92.

  • Cramer: 4 strong stocks for months to come Wednesday, 9 Jul 2014 | 6:29 PM ET

    If the charts are to be believed, the path of least resistance for these 4 stocks should be higher.